Alzheimer’s research is progressing towards earlier diagnosis, treatments that can slow cognitive decline and a better understanding of the biological processes behind the disease. Recent developments are broadening the range of approaches being investigated, although significant challenges remain and current treatments cannot cure the condition.
Alzheimer’s disease is associated with changes in the brain, including the accumulation of amyloid plaques and abnormal tau proteins. These changes can disrupt communication between brain cells and contribute to memory loss, difficulties with reasoning and changes in behaviour. Researchers are increasingly examining how these processes interact with inflammation, blood vessel health and other biological factors.
For decades, research focused heavily on the role of amyloid, a protein that can accumulate in the brain. This approach has led to the development of treatments that target amyloid plaques, including lecanemab and donanemab. Both drugs have been approved in the United States for people with early-stage Alzheimer’s disease and have demonstrated an ability to slow cognitive decline in some patients. However, they do not reverse existing damage, and treatment can carry serious risks, including brain swelling and bleeding. Their use therefore requires careful patient assessment and monitoring.
The development of these medicines represents a change in treatment options, but their benefits remain limited. They are intended for people in the early stages of the disease, rather than those with advanced Alzheimer’s. Researchers are continuing to investigate how treatment can be made more effective and whether different approaches could eventually be combined to produce better outcomes.
The broader understanding of Alzheimer’s is expanding. Scientists are examining the role of inflammation and the relationship between metabolic health, cardiovascular conditions and cognitive decline. This could lead to treatments that address several biological processes rather than concentrating on a single protein. However, the precise contribution of these factors varies, and research has yet to establish which combinations of treatments will deliver the greatest benefits.
Early diagnosis is another important area of development. Identifying Alzheimer’s before substantial damage has occurred could allow patients to access suitable treatment sooner. Blood tests designed to detect disease-related biomarkers are being developed and introduced into clinical practice, providing additional tools to support diagnosis. These tests may help clinicians determine whether further investigations or specialist assessments are required.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.
